publication date: Apr. 3, 2015
20150403 - Apr. 3, 2015
ISSUE 13 – APRIL 3, 2015PDF

Over 48 Hours, Power Shifts at NCI, ACS, Dana-Farber and MD Anderson

Over the first two days in April, massive leadership changes occurred at top institutions in cancer research:

• On April 1, the top job at NCI switched from Harold Varmus to Douglas Lowy, with the Lowy being formally named acting director.

• On April 1, Edward Benz announced his plans to leave presidency at Dana-Farber Cancer Institute, and the institution’s board began the search for his successor.

• On April 2, the American Cancer Society announced that the job of CEO would go to former Johnson & Johnson executive Gary Reedy.

• On April 2, the UT System announced that Lynda Chin will be vacating her jobs as head of genomic medicine and scientific director of a research institute she co-founded. Chin, who is married to MD Anderson President Ronald DePinho, came to Houston from Dana-Farber as a team in 2011.

Resolving Disputes in Precision Medicine: The Question of CYP2D6 Remains Open

What does it take to declare that a scientific dispute is resolved? 

A long-running argument over the role of a biomarker in the treatment of breast cancer illustrates a challenge that runs through the heart of precision medicine: the absence of mechanisms for resolving disagreements between scientists.

The story of CYP2D6, a mutation that may (or may not) predict the manner in which the patient metabolizes the cheap, widely used drug tamoxifen, is of the sort that makes insiders shake their heads.

The question is relevant to an estimated 150,000 newly diagnosed estrogen receptor-positive breast cancer patients a year in the U.S. alone.

A Biomarker Court? Who Should Decide?

Answers from: Carmen Allegra, Lisa McShane, Robert Cook-Deegan, Barnett Kramer, Frances Visco, and FDA

No pharma company is clamoring to get a response to the question of significance of CYP2D6. 

Since an estimated 7 percent of newly diagnosed breast cancer patients are poor metabolizers of tamoxifen, perhaps as many as 93 percent are good candidates for receiving this cheap generic drug. 

Cold Spring Harbor Laboratory And North Shore-LIJ to Form $120 Million Collaboration

Two New York institutions—Cold Spring Harbor Laboratory and the North Shore-LIJ Health System—announced a $120 million cancer research collaboration on April 2.

The collaboration aims to develop a clinical cancer research unit at the North Shore-LIJ Cancer Institute’s headquarters in Lake Success, N.Y., support early-phase clinical studies, and recruit and train clinician-scientists.

North Shore-LIJ and CSHL will continue as independent organizations governed by their respective boards of trustees. The sources of funds for the collaboration were not disclosed.

In Brief

  • Lewis Cantley to Deliver Takamatsu Lecture at AACR Annual Meeting

  • Lucille Adams-Campbell to Deliver Minorities in Cancer Research Lecture at AACR Annual Meeting

  • Robert Gentleman appointed vice president of computational biology at 23andMe Inc.

  • Aleksandar Zafirovski named associate director for administration for Lurie Cancer Center at Northwestern University

  • Scripps Clinic Medical Group acquires three radiation oncology services

  • Aeterna Zentaris to transfer library of 100,000 compounds to center at Medical University of South Carolina

  • GlaxoSmithKline to establish third global center for vaccine research in Rockville, Md.

Drugs and Targets

  • FDA approves Jadenu, an oral formulation of Exjade

  • FDA grants priority review to Kyprolis

  • FDA updates label for Zytiga plus prednisone in metastatic castration-resistant prostate cancer

  • MD Anderson Cancer Center and Astellas Pharma Inc. sign option agreement for AML research

  • Eli Lilly and OncoMed Pharmaceuticals to evaluate combination of demcizumab and Alimta

  • Merck and Syndax Pharmaceuticals to evaluate combination of Keytruda and entinostat

  • Intrexon Corporation and Merck Serono to collaborate on CAR-T cancer therapies

Copyright (c) 2020 The Cancer Letter Inc.